Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,717,852

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,717,852
Title:Cartridge holder and pen-type injector
Abstract: A cartridge holder for a drug delivery device is presented having snap fastening connection means to fasten the cartridge holder to a housing of the drug delivery device, wherein the fastening connection means are provided with at least on basically rectangular window for receiving a locking element of said housing. The invention is further directed to a pen-type injector equipped with a respective snap fastening connection for the cartridge holder.
Inventor(s): Einwachter; Robin (Frankfurt am Main, DE)
Application Number:14/391,055
Patent Claim Types:
see list of patent claims
Delivery; Device; Dosage form;

Drugs Protected by US Patent 9,717,852

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081-002 Apr 27, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sanofi Aventis Us APIDRA SOLOSTAR insulin glulisine recombinant INJECTABLE;SUBCUTANEOUS 021629-003 Feb 24, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196-002 Dec 11, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,717,852

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
12163800Apr 11, 2012
PCT Information
PCT FiledApril 08, 2013PCT Application Number:PCT/EP2013/057270
PCT Publication Date:October 17, 2013PCT Publication Number: WO2013/153011

International Family Members for US Patent 9,717,852

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 090632   Start Trial
Australia 2013247058   Start Trial
China 104220113   Start Trial
Denmark 2836259   Start Trial
European Patent Office 2836259   Start Trial
Spain 2588510   Start Trial
Hong Kong 1201769   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.